Comparison of antimicrobial resistance patterns of ESBL and non ESBL bacterial isolates among patients with secondary peritonitis at Bugando Medical Centre, Mwanza – Tanzania by Jeremiah Seni et al.
RESEARCH ARTICLE Open Access
Comparison of antimicrobial resistance
patterns of ESBL and non ESBL bacterial
isolates among patients with secondary
peritonitis at Bugando Medical Centre,
Mwanza – Tanzania
Jeremiah Seni1*†, Enock Sweya1†, Amri Mabewa2,3†, Stephen E. Mshana1 and Japhet M. Gilyoma2,3
Abstract
Background: Secondary peritonitis is a common surgical emergence with deadly outcomes when not timely
and promptly intervened. The emergence of Extended spectrum beta lactamase producing bacteria (ESBL) poses
treatment challenge at Bugando Medical Centre (BMC); hence a need to evaluate the magnitude of ESBL so as to
guide specific therapy.
Methods: This was a cross sectional study conducted at BMC from May 2014 to April 2015 involving patients
with secondary peritonitis. A questionnaire was used to collect patients’ information. Peritoneal aspirate sample
was collected intra-operatively and processed using standard operating procedures to identify bacteria species
and their susceptibility profiles.
Results: The study involved 97 patients with the median age (IQR) of 32 (21–47) years, males were 62 (63.9 %)
and about 27 (27.8 %) patients had co-morbid illnesses. The prevalence of ESBL among patients with secondary
peritonitis was 23.7 % (23/97). Of 53 gram negative Enterobacteriaceae isolated, 47.2 % (25/53) were ESBL producers,
with predominance of Escherichia coli 7 (28.0 %) and Klebsiella spp 5 (20.0 %). The ESBL isolates exhibited more
resistance rates to trimethoprim sulfamethoxazole and ciprofloxacin compared to non ESBL isolates 96.0 % versus 60.
7 %, p value = 0.003 and 16.0 % versus 0.0 %, p value = 0.043 respectively). All isolates were sensitive to meropenem.
Conclusions: The prevalence of ESBL among patients with secondary peritonitis at BMC is high; with more resistance
rates among ESBL compared to non ESBL isolates. There is a need for strengthen ESBL surveillance in this setting so as
to guide specific therapy.
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Background
Peritonitis is the inflammation of peritoneum, the layer
which enclose many organ in the abdomen [1]. Of the
three types of peritonitis, secondary peritonitis has a
major clinical impacts due to loss of integrity in hollow
viscus resulting into perforation and is the most
common form of peritonitis encountered in surgical
practice causing significant morbidity and mortality
when not timely and promptly intervened [1–4]. The
most common causes of secondary peritonitis are perfo-
rated peptic ulcer disease, perforated small and large in-
testine, intestinal obstruction and many others [3–6].
The complications of secondary peritonitis are signifi-
cant and include perforated viscus, hypovolemic shock,
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The emergence of extended-spectrum beta lactamase
(ESBL)-producing gram-negative infection in the past
decade has made the management of gram-negative in-
fections more difficult [7–9]; this in turn has necessi-
tated a need to explore the magnitude of this problem
across countries so as to confer specific therapy. It is
well known that Gram negative bacteria of the family
Enterobacteriaceae predominates in causing secondary
peritonitis partly due to the close proximity and the pos-
sibility of translocation between peritoneum and bowel
[1, 10, 11].
At Bugando Medical Centre (BMC), secondary peri-
tonitis is the commonest indication for admission in the
surgical wards; it is associated with significant workload,
severe complications and deaths [6, 12, 13]. In our re-
cent work at BMC, we delineated the etiology, treatment
outcome and prognostic factors associated with second-
ary peritonitis [6]. To ensure rational antimicrobial ther-
apy to patients with secondary peritonitis, this study was
conducted to determine the proportion of bacteriologic-
ally confirmed patients with secondary peritonitis due to
ESBL and their drug susceptibility profiles.
Methods
Study design, site and population
This was a cross sectional hospital based study con-
ducted from May 2014 to April 2015 at BMC in
Mwanza region Tanzania involving 97 patients with sec-
ondary peritonitis admitted at BMC who consented to
participate in the study.
Data collection and laboratory procedures
A pre-structured questionnaire was used to collect
demographic and clinical data among consented pa-
tients. Approximately 5–8 ml of peritoneal aspirate sam-
ple was collected intra-operatively by the surgeon/
resident and transported in the Catholic University of
Health and Allied Sciences (CUHAS) multipurpose la-
boratory for processing within two hours using sterile
swabs with Stuart’s transport media.
Gram stain for each sample was done followed by culture
into Blood Agar, MacConkey Agar and Salmonella Shigella
Agar (HI MEDIA, INDIA) and the plates incubated at 35–
37 °C for 18–24 h. All gram negative bacteria were identi-
fied initially basing on lactose fermentation reaction on
MacConkey agar. Then followed by in-house biochemical
identification tests such as oxidase, citrate, urease, Triple
sugar iron (TSI) and Sulphur indole motility (SIM) reac-
tions [14]. Susceptibility testing was done using disc diffu-
sion method basing on the Clinical Laboratory Standard
Institute (CLSI) guideline [15]. The antibiotic discs tested
included ampicillin (10 μg), trimethoprim/sulfamethoxazole
(1.25/23.75 μg), chloramphenicol (30 μg), ciprofloxacin
(5 μg), gentamicin (10 μg), amoxicillin/clavulanate (20/10 μg),
ceftriaxone (30 μg), ceftazidime (30 μg), and meropemen
(10 μg) (HI MEDIA, INDIA). The isolates were simultan-
eously screened for ESBL production in the same Muller
Hinton Agar by using disc approximation method. Ceftaz-
idime (30 μg) and Ceftriaxone (30 μg) discs were placed
equidistant from the Amoxycillin/clavunate (20/10 μg)
disc; enhanced zone of inhibition towards amoxycillin/cla-
vunate disc were considered as positive result for ESBL
production [7, 15, 16].
Quality control
Standard laboratory procedures was strictly adhered.
Escherichia coli ATCC 25922 and Escherichia coli ATCC
35218 and Klebsiella pneumoniae ATCC 700603 were
used as negative and positive ESBL controls respectively
for all laboratory procedures.
Data management and analysis
Every participant had a unique identification number in-
dicated on the questionnaire. The data and results were
entered into a log book and later sorted and transferred
into Microsoft excel for consistent checks and data
cleaning. Data analysis was done using STATA ver-
sion11.0 according to the objectives of the study. Results
were presented into percentages/proportions for cat-
egorical variables, whereas median (interquartile range)
was used to summarize the continuous variables and
compared using Wilcoxon rank sum test. The chi-
square (Fisher's exact where appropriate), p-value and
odd ratio at 95 % confidence interval were used to test
the significance association between ESBL-associated
secondary peritonitis with deaths as well as comparison
of resistance profiles between ESBL and non ESBL bac-
terial isolates.
Results
Of the 97 patients with secondary peritonitis enrolled in
this study, males were 62 (63.9 %). The median age
(IQR) of participants was 32 (21–47) years, the mini-
mum age was 5 years and the maximum age was
86 years. Majority of patients were primary school
leavers 58 (59.8 %), with no employment 61 (62.9 %) and
were from urban areas 51 (52.6 %). The study showed
that about 13 (13.4 %) of enrolled patients were HIV
seropositive and 27 (27.8 %) had co- morbidity (Table 1).
The proportion of patients with secondary peritonitis
confirmed bacteriologically were 57.7 % (56/97); giving a
total of 60 bacterial isolates (about 4 patients had double
infections). The most common bacteria were Escherichia
coli, 19 (31.7 %) and Klebsiella spp, 10 (16.7 %) (Table 2).
The prevalence of ESBL among patients with second-
ary peritonitis was 23.7 % (23/97). Of the Gram negative
Enterobacteriaceae, 47.2 % (25/53) were ESBL producers;
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with majority being Escherichia coli 7 (28.0 %), and Kleb-
siella spp 5 (20.0 %) (Table 3).
There was a high resistance to ampicillin (100.0 %),
amoxicillin-clavulanate (71.4–100.0 %) and
trimethoprim-sulphamethoxazole (63.2–90.0 %); as op-
posed to low resistance rates to chloramphenicol (5.3–
37.5 %), ciprofloxacin (0.0–15.8 %) and meropenem
(0.0 %) (Table 4).
The ESBL isolates exhibited more resistance profiles in
all antimicrobial agents compared to non ESBL isolates;
the resistance rates to non beta lactam antibiotics like
trimethoprim sulfamethoxazole and ciprofloxacin were
significantly higher among ESBL isolates as opposed to
non ESBL isolates (96.0 % versus 60.7 %, p value = 0.003
and 16.0 % versus 0.0 %, p value = 0.043 respectively)
(Table 5).
Although not significant, the proportions of patients
who died was higher in ESBL-associated peritonitis
group than non ESBL- associated secondary peritonitis
group [21.7 % (5/23) versus 15.2 % (5/33) respectively,
OR (95 % CI) = 1.56 (0.39–6.14); p value = 0.528).
The duration of hospital stay was relatively higher
among patients with ESBL compared to those without
ESBL [7 (6–16) days versus 6.5 (5–8) days; p-value
0.229)], despite the fact that no significant association
was found.
There was no statistical association between ESBL as-
sociated secondary peritonitis with age, sex, residence,
occupation, HIV serostatus and comorbid illness.
Discussion
The magnitude of ESBL attributable infections is pro-
gressively growing all over the world with noticeable
variation across countries and in difference clinical con-
ditions [9]. This study showed high proportion of ESBL
(47.2 %) among bacteria isolated from patients with sec-
ondary peritonitis. Similarly, higher prevalence rates be-
tween 70 and 86.5 % have been reported in Uganda,
Ethiopia and India [17–19] as opposed to low prevalence
rates of approximately 4.9–14.5 % reported in Nether-
land and Spain [20, 21]. Moreover, there is an increase
in the magnitude of ESBL in Mwanza from 29.2 % in
2009; 35 % in 2014 and to 47.2 % in the present study in
2015 [7, 22]. The high prevalence in developing coun-
tries as opposed to developed countries may be due to
lack of strict policies on the rational use of antimicrobial
agents as well as lack of stringent measures on infection
control and prevention strategies.
This study showed that the ESBL producing E.coli and
Klebsiella spp were the leading organisms in patients
with secondary peritonitis in approximately 28 and 20 %
respectively. The findings are also similar to many other
studies in different countries [8, 10, 11, 18, 19, 21]. The
predominance of these species may be due to their pres-
ence as normal flora in the gastrointestinal tract and the
Table 1 Social demographic and clinical characteristics of the
study participants
Parameter Number Percentages (%)
Sex Female 35 36.1 %
Male 62 63.9 %
Residence Urban 51 52.60 %
Rural 46 47.40 %
Education Informal 14 14.40 %
Primary 58 59.80 %
Secondary 25 25.80 %
Occupation Employed 20 20.60 %
Unemployed 61 62.90 %
Under 18 16 16.50 %
HIV Negative 84 86.60 %
Positive 13 13.40 %
Co-morbiditya No 70 72.20 %
Yes 27 27.80 %
aPuerperal sepsis (4), HIV (12), Severe anaemia (4), Hypertension (4), Tumor (1),
Heart failure (1), Renal failure (1), HIV & Hypertension (1)
Table 2 Bacterial isolates from patient with secondary peritonitis
at BMC
Bacteria Frequency Percentage (%)
Escherichia coli 19 31.7
Klebsiella spp 10 16.7
Citrobacter spp 9 15.0
Enterobacter spp 3 5.0
Salmonella spp 2 3.3
Serratia marcescens 1 1.7
Unidentified Enterobacteriaceae 7 11.6
Othersa 9 15.0
Total 60 100.0
aPseudomonas aeruginosa (2), Morganella morganii (1), Proteus vulgaris (1),
Staphylococcus spp (2), Streptococcus spp (2), and Enterococcus spp (1)
Table 3 Proportions of ESBL among Enterobacteriaceae
bacterial species
ESBL Frequency Percentage (%)
Escherichia coli 7 28.0
Klebsiella spp 5 20.0
Citrobacter spp 4 16.0
Enterobacter spp 3 12.0
Salmonella spp 1 4.0
Serratia marcescens 1 4.0
Unidentified Enterobacteriaceae 4 16.0
Total 25 100.0
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possibility of traversing to the peritoneal cavity due to
anatomic close proximity.
Similar to other studies, majority of ESBL isolates
showed high resistance to commonly used antimicrobial
agents such as trimethoprim sulfamethoxazole (>80 %)
as opposed to less commonly used antimicrobial agents
such as ciprofloxacin and imipenem [10, 18, 19]. More-
over, the resistance rates in various antimicrobial agents
were shown to be higher among ESBL isolates as op-
posed to non ESBL isolates reiterating the need to have
laboratory guided screening strategy in this setting, so as
to timely identify patients with ESBL associated infec-
tions and thus, provide specific therapy.
Despite the fact that there was no statistical signifi-
cance, the study showed that the proportions of patients
who died was more in the ESBL-associated secondary
peritonitis group than non ESBL- associated secondary
peritonitis group calling for a large prospective study
with large sample size to ascertain these findings. High
mortality in patients with multi drug resistance bacterial
infections have also being reported in in other studies in
Tanzania, Uganda and Spain [11, 19, 23]. Therefore
these findings, emphasize on the negative impact of
multi-drug resistant bacteria and hence a need for con-
tinuous antimicrobial resistance surveillance so as to
guide specific therapy and better outcome among
patients.
Study limitations
Anaerobic culture was not done in the present study
due to lack of facilities for this technique; this may
underestimate the actual number of bacteria involved in
secondary peritonitis.
Conclusions
The prevalence of ESBL among patients with secondary
peritonitis at BMC is high (23.7 %). There is also high
proportion of Gram negative Enterobacteriaceae
(47.2 %) exhibiting ESBL phenotype; with majority of
these isolates being E.coli and Klebsiella spp. Moreover,
there is a growing problem of ESBL in Mwanza -
Tanzania for the past 6 years. Although not statistically
significant, patients with ESBL associated secondary
peritonitis were more likely to die as opposed to those
without ESBL.
There is a need to have a continuous ESBL surveil-
lance at BMC so as to guide specific antimicrobial ther-
apy. A study to evaluate the impact of anaerobic bacteria
should be carried out in this setting, so as to assess their
impact among patients with secondary peritonitis.
Table 4 Antimicrobial resistance profiles of the 53 Enterobacteriaceae bacterial species
Antimicrobial agent Bacterial resistant patterns
E.coli (19) Klebsiella spp (10) Citrobacter spp (9) Unidentified (7) *Others (8)
n (%) n (%) n (%) n (%) n (%)
AMP 19 (100.0) 10 (100.0) 9 (100) 7 (100) 8 (100.0)
C 1 (5.3) 1 (20.0) 2 (22) 2 (29) 3 (37.5)
AMC 18 (94.7) 9 (90.0) 8 (88.9) 5 (71.4) 8 (100.0)
CTR 7 (36.8) 4 (40.0) 4 (44.4) 4 (57.1) 5 (55.6)
CAZ 10 (52.6) 4 (40.0) 4 (44.4) 5 (71.4) 3 (55.6)
CO 12 (63.2) 9 (90.0) 8 (89) 5 (71.0) 7 (87.5)
GE 1 (5.3) 3 (30.0) 0 (0) 3 (43.0) 1 (25.0)
CIP 3 (15.8) 1 (10.0) 0 (0.0) 0 (0.0) 0 (0.0)
MEM 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
AMP ampicillin, C chloramphenicol, AMC amoxycillin-clavulanate, CTR ceftriaxone, CAZ ceftazidime, CO trimethoprim – sulfamethoxazole, GE gentamicin,
CIP ciprofloxacin, MEM meropenem, n number of resistant bacterial species.
*Others: Enterobacter spp (3), Salmonella spp (2), Serratia marcescens (1), Morganella morganii (1), and Proteus vulgaris (1)
Table 5 Comparison of antimicrobial resistance profiles of 25
ESBL and 28 non ESBL isolates
Antimicrobial agent Bacterial resistant patterns p value
ESBL (n = 25) Non ESBL (n = 28)
n (%) n (%)
AMP 25 (100.0) 28 (100.0) -
C 7 (28.0) 2 (7.1) 0.067*
AMC 25 (100.0) 23 (82.1) 0.053*
CTR 25 (100.0) 0 (0.0) <0.001*
CAZ 25 (100.0) 2 (7.1) <0.001*
CO 24 (96.0) 17 (60.7) 0.003*
GE 4 (16.0) 4 (14.3) 1.000
CIP 4 (16.0) 0 (0.0) 0.043*
MEM 0 (0.0) 0 (0.0) -
ESBL extended spectrum beta lactamase producer, AMP ampicillin, C
chloramphenicol, AMC amoxycillin-clavulanate, CTR ceftriaxone,
CAZ ceftazidime, CO trimethoprim – sulfamethoxazole, GE gentamicin,
CIP ciprofloxacin, MEM meropenem, n number of resistant bacterial species
*Fisher’s exact
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